Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily

Gordon M. Riha, Philbert Y. Van, Jerome A. Differding, Martin A. Schreiber

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

BACKGROUND: The purpose of this study was to analyze whether 2 standard dosing regimens of enoxaparin (30 mg twice daily vs 40 mg once daily) would result in different deep vein thrombosis (DVT) rates and anti-factor Xa activity (anti-Xa) in surgical patients. METHODS: Patients who required enoxaparin for prophylaxis were followed prospectively. Demographics were recorded. Patients underwent standardized duplex screening. Peak anti-Xa levels were drawn on 4 consecutive days. RESULTS: Sixty-three patients were followed up (28 patients on 30 mg twice daily, 35 patients on 40 mg once daily). There was no significant difference in demographics between groups. Twenty-five percent of patients on 30 mg twice daily developed a DVT, whereas 2.9% of patients on 40 mg once daily developed a DVT. Patients on 30 mg twice daily had significantly lower anti-Xa levels. CONCLUSIONS: The incidence of DVT is increased in surgical patients who receive 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. Dosing of 40 mg once daily results in significantly higher peak anti-Xa levels compared with 30 mg twice daily.

Original languageEnglish (US)
Pages (from-to)598-602
Number of pages5
JournalAmerican journal of surgery
Volume203
Issue number5
DOIs
StatePublished - May 2012

Keywords

  • 30 BID
  • 40 QD
  • DVT
  • Enoxaparin
  • Surgery
  • Thrombosis

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily'. Together they form a unique fingerprint.

Cite this